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The reported birth of genetically modified twins in late 2018 has given new fuel to debates 
about the ethics of germline genome editing (GGE). There is a broad consensus among 
stakeholders that clinical uses of GGE should be temporarily banned as the technology is not 
yet deemed safe for use in humans. However, the idea of a complete ban is dismissed by 
many based on the expectation that more research will eventually allow scientists to make 
the technology safe without having to put humans at risk first. In this paper, I will analyse 
this assumption and argue that it is undermined by recent developments in the 
postgenomic life sciences. In particular, I will argue that in a postgenomic view of germline 
editing a complete ban on specific uses of the technology is warranted, because the 




Researchers have been able to modify the genomes of living systems for almost 50 years, 
but technical limitations meant that precise DNA manipulation could not be achieved in 
higher eukaryotes such as humans. Only in the last decade (roughly) did targeted genome 
editing become a widely applicable technology that allows researchers to remove, insert or 
even re-write specific DNA sequences in almost any organism with great precision.1 
 
Scientists usually distinguish between the genetic modification of somatic cells and that of 
germline cells. Several somatic applications of genome editing technologies are currently 
being developed2 and these interventions are often seen as ethically less challenging a) 
because of the more local or contained character of the modification and b) because 
existing ethical and legal frameworks are already in place to deal with such interventions.3 
Germline genome editing (GGE), in contrast, has been more controversial, mainly because 
germline cells pass on their genetic material (and hence the modifications they might carry) 
to future generations. Importantly, as germline modification automatically happens if 
zygotes are targeted the debate about GGE has primarily focused on the use of genome 
editing technologies in early-stage human embryos. 
 
GGE has the potential to deliver great benefits but also to create significant harm, both to 
the targeted individuals as well as to future generations. The risks associated with the use of 
GGE in humans – combined with reports of first laboratory-based trials in human embryos in 
20154 – led a range of stakeholders to call for either a complete ban on the use of the 
technology5 or a temporary ban of clinical applications.6 Calls for a limited ban of clinical 
applications have been re-issued and further developed in early 2019 in response to the 
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reported birth of genetically modified twins in China.7 The Chinese trials, the goal of which 
was to make the children resistant to HIV infection, were widely condemned by the 
scientific community, not only because the technology is not deemed safe yet but also 
because they violated widely accepted ethical and clinical standards.8  
 
1.1. A Prudent Way Forward? 
While at first sight calls for a complete ban seem more radical than calls for a temporary 
ban, it could be argued that in many ways the latter is the more radical and interesting 
proposal. Calls for a temporary ban are based on a range of crucial assumptions, in 
particular a fundamental dichotomy between a research context and a clinical context. The 
former includes all applications of genome editing in which modified embryos are not 
implanted, and not allowed to develop beyond 14 days.9 The clinical use consists of 
applications in which modified embryos are implanted and brought to term, thus giving rise 
to a modified human being that could – potentially at least – further reproduce. Because of 
the containment (i.e. destruction) of the modified embryos the research use is seen by 
many as safe. Clinical uses, however, are seen as risk-laden.  
 
A key idea that underlies calls for a temporary ban is that more research, including research 
uses of GGE, will allow scientists to further develop the technology so that the risks involved 
with clinical applications could eventually be eliminated or reduced to the point where they 
become morally acceptable. This research-based approach constitutes what some have 
called a ‘prudent’ way forward10 as it allows researchers to unleash the benefits of the 
technology without having to put humans at risk of harm. It is also an exercise in trust-
building, as researchers want to demonstrate to policy makers and the broader public that 
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they are capable of self-regulation and that they can proceed without putting humans and 
future generations at risk.11 
 
But this prudent way forward raises many questions, in particular regarding the role of 
research and its strict separation from any clinical uses of the technology. Clearly, there are 
high expectations put on research and the kind of guidance it can deliver on its own. In fact, 
the whole idea of a temporary and restricted ban of GGE builds on the power of research 
and its safety. If the risks involved in clinical applications could not be reduced, then there 
would be no point in calling for a merely temporary ban. And if the research needed to 
reduce the risks were as risky as the clinical applications themselves then it would again not 
be possible to make the ban temporary. In fact, in this case the ban would have to be 
extended to research uses of GGE. 
 
Given the centrality of the concept of a safe and clearly demarcated research context it is 
important to understand what this context is supposed to entail and deliver. What 
conditions have to be met to realise a risk-free elimination (or significant reduction) of the 
risk factors of GGE?12 And is it indeed possible to have such a safe and hence prudent way 
forward before any clinical applications of GGE are realised? 
 
Here I want to address these questions by looking at a specific example of a call for a 
temporary ban of clinical uses. I will first analyse how its advocates portray the benefits of 
GGE (section 2) and its risks (section 3). In this analysis I will in particular focus on the role 
assigned to research within the overall pursuit of GGE. I will then argue that many of the 
conditions that would have to be fulfilled for research to deliver what it is asked to do are 
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not attainable because they are built on a picture of the genome that has been undermined 
by new work in the genomic (or better: postgenomic) sciences (section 4). This, I will argue, 
undermines the idea that there could be a clear distinction between a safe research context 
and clinical applications of the technology when dealing with common diseases (section 5). 
This has important consequences for how we approach GGE and its further development. In 
a postgenomic world the development of GGE for treating common diseases becomes so 
fraught with potential risks that its pursuit is not ethically defensible. An exception to this 
are some cases of rare monogenic diseases and somatic uses of genome editing. 
 
2. The Idea of a Temporary Ban of GGE 
Calls for a temporary ban of clinical uses of GGE first emerged in 2015 when reports of 
laboratory-based genome editing experiments in human embryos began to circulate. They 
were repeated and further specified over the following years in a range of publications, 
most recently in early 2019 in response to the first clinical uses of the technology in China.13  
 
The argument made in these calls is, at first sight at least, relatively simple: GGE should not 
be used in clinical applications until more research has been done to establish its safety.14 
This straightforward proposal, however, builds on a range of assumptions, not just about 
the risks and benefits of the technology but also about the nature of biological systems and 
the research used to study them. To better understand and assess the proposed temporary 
bans it is therefore instrumental to first get a better understanding of the different 
assumptions that underlie them.  
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In what follows I will take a closer look at one particular defence of a temporary ban, 
namely the analysis provided by Gyngell and co-workers in a paper titled ‘The Ethics of 
Germline Gene Editing’.15 In line with other positions, Gyngell and colleagues argue against 
a blanket ban of GGE and advocate a temporary ban on clinical uses of the technology. Their 
careful argument consists of two parts: first they argue that both the clinical and the 
research uses of GGE could provide clear benefits for humanity. Second, they claim that 
these benefits outweigh (or might eventually outweigh) the potential harm caused, as long 
as more research can establish the safety of the technology when applied in humans. This 
leads them to conclude that the pursuit of GGE (minimally defined as the research use of 
GGE and the funding of such research) is not only morally permissible but also morally 
desirable. 
 
2.1 The Benefits of Using GGE for Research 
Gyngell et al. highlight several reasons why the research use of GGE is beneficial. One crucial 
advantage of GGE is that it allows researchers to introduce targeted changes in an embryo’s 
genome. This will allow them to gain deeper insights into the role specific DNA segments 
and their products (in case open reading frames are targeted) play in early human 
development.16  
 
This will not only provide important benefits for our general understanding of human 
biology, but it might also help further improve other medical technologies, such as in vitro 
fertilisation (IVF). As Gyngell et al. highlight, such non-GGE-based clinical applications have 
become a key driver of the research use of GGE. 
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Gyngell and colleagues also highlight that targeted gene editing can be used to create 
modified human embryonic stem cells that can serve as models for genetic diseases. This 
allows researchers to work directly with human cells and hence to rely less on the use of 
(potentially flawed) model organisms.17 Modified embryonic stem cells also have the 
potential to serve as future therapeutic tools for a range of conditions. 
 
These different applications give good reasons for why the research use of GGE should 
continue, in particular because it poses no or very little risks to humans (as modified 
embryos can be relatively easily contained). The research use also has an important role to 
play as an enabler of future clinical applications of GGE. I will return to this point in section 
3.1. 
 
2.2 The Benefits of Using GGE in the Clinic 
When it comes to clinical applications of GGE monogenic diseases (such as cystic fibrosis, 
Huntington’s disease, or haemophilia) are currently seen as the most promising targets of 
the technology. Scientists already have a relatively good understanding of the genetics of 
these conditions and the promise is that germline editing will allow researchers to remove 
or replace the disease-causing DNA sequence in affected embryos thereby making sure that 
they (and their potential offspring) are free from the disease. Importantly, some of these 
conditions are difficult or impossible to tackle via somatic gene editing as the latter does not 
allow researchers to edit the affected sequence in all cells of the organism. This means that 
germline editing might be the only (or at least the most promising) route to success for a 
number of these conditions. To date several disease-causing genes have already been 
targeted by researchers in human embryos using genome editing tools as part of 
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(laboratory-based) proof-of-principle studies. An example is a Chinese study that used 
CRISPR-Cas9 in human embryos to correct the mutation that causes β-thalassemia.18  
 
Some authors have argued that GGE is not needed to deal with monogenic conditions as 
there are alternative ways for parents to avoid passing on the disease-causing mutation(s) 
to their offspring. Of particular importance here is the idea that prospective parents can use 
IVF and preimplantation genetic diagnosis (PGD) to select mutation-free embryos for 
implantation.19 However, it has also been highlighted that this strategy will not work in all 
cases. If, for instance, both parents are homozygous for a recessive disorder or if one is 
homozygous for a dominant disorder then genetic selection via IVF/PGD will not be possible. 
It has also been argued that the IVF/PDG strategy will not always provide doctors with 
enough viable embryos to select from.20 This means that in a few (and arguably rare) 
circumstances GGE will be the most promising route to success for affected families.  
 
 
Apart from its use to tackle monogenic diseases, the technology’s main and probably 
broadest appeal arises in the context of ‘complex’ or ‘common’ diseases (such as cancer, 
diabetes or heart disease). Clearly all of these conditions cause significant harm to the 
people they affect and they also represent crucial challenges for public health systems. The 
prospect of having a new way of eliminating or at least significantly reducing the risk of 
these conditions is seen by Gyngell et al. and others as a key reason to support the 
development and potential use of GGE. 
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One aspect that makes it difficult to deal with complex diseases at the genomic level is the 
fact that more than one stretch of DNA can play a role in their aetiology. To see any positive 
effects of a genomic intervention it will therefore be necessary to target a range of genomic 
loci. Dealing with polygenic conditions has so far been beyond the reach of existing 
approaches (for instance the combination of IVF and PDG or also traditional gene therapy 
using viral vectors). But, as Gyngell et al. highlight, new gene editing tools now allow 
researchers to target several genomic loci at once.21 This means that, technically at least, 
targeting complex diseases is becoming a feasible project.22 
 
The potential short-term benefits of GGE (the research use and the treatment of monogenic 
diseases) and the long-term prospects (tackling complex diseases) form the core benefits 
that pursuing GGE in humans could provide and motivate opposition to a complete ban of 
the technology. But there are of course also potential costs associated with the pursuit of 
GGE. One issue that dominates the current debate are safety concerns, in particular the 
safety of clinical applications of the technology. I will turn to these potential downsides in 
the next section and highlight why the research use becomes so important in this context. 
 
3. What is Holding Us Back? Risks Associated with GGE and the Need for More Research 
There are two types of safety issues that come up in the context of GGE: off-target effects 
and unintended consequences of on-target modifications. The consensus amongst 
stakeholders and commentators is that these risks have to be eliminated or at least 
significantly reduced before researchers can move to the clinical context and reap the 
potential benefits of GGE in humans.23  
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3.1 Off-target Modifications 
A key worry when using genome editing tools in living systems are the so-called off-target 
effects. By this researchers mean that the intervention could introduce changes in parts of 
the genome that were not targeted. Such unintended modifications can have devastating 
effects on the organism as they could, in the worst case, lead to cancer or other severe 
conditions. Such drastic outcomes might be relatively rare but they are certainly a 
possibility. 
 
Whilst the last few years have seen vast improvements in the precision of the available 
editing tools there is still a significant risk that the intervention goes astray and will 
introduce unintended changes in the DNA. There have been some reports of interventions 
in human embryos that showed no off-target effects24 but these claims have been 
questioned by other researchers in the field.25 Off-target effects are also still an issue in 
other systems such as Arabidopsis or mice.26 
 
Because of the risks that off-target effects pose it is not feasible to pursue a learning-by-
doing approach, i.e. to develop clinical applications through cycles of practice and 
optimisation. This is where the distinction between a research context and clinical 
applications of genomic interventions becomes central to the debate about GGE. The 
research context is not only seen as safe but also as a potential enabler of future clinical 
uses that can help to reduce or eliminate the risks associated with GGE before clinical 
applications are even attempted. 
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This is already being done in the context of off-target modifications. One research avenue 
that is currently being explored is to find new editing molecules that can perform the same 
task as existing tools but that can do so with more precision.27 Another avenue that is being 
explored is to optimise the currently used enzymes through a method called ‘directed 
evolution’.28 This method allows researchers to create and test new variants of an enzyme 
in vitro, to select the best performer of the batch and to then repeat the whole procedure 
with this new enzyme using more stringent test conditions. By going through this cycle 
several times the performance of existing enzymes can be boosted or new functionalities 
can be introduced over time. This method has already been used to optimise the 
performance of CRISPR-Cas9, the main tool currently used in genome editing.29 
 
Clearly, this path forward relies on more than just the research use of GGE. We have here a 
general research context that is separated from clinical uses of GGE and that is safe, as no 
humans are exposed to harm (directed evolution, for instance, is a microbe-based research 
system). This supports the general idea behind the concept of a temporary ban, i.e. the idea 
that safe research can be used to eliminate or reduce risk factors that currently make 
clinical applications not feasible. 
 
It could be objected that this research will not be complete without the use of GGE in 
human embryos. After all, once new or optimised editing enzymes have been identified they 
will have to be tested in human embryos to verify their precision in situ. This could mean 
that the research context is not as safe and unproblematic as the above discussion implies. 
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However, the research needed to establish whether off-target modifications have occurred 
or not does not require that modified embryos are implanted and brought to term. Off-
target effects are created at the point of intervention. This means that modified embryos 
can be analysed as soon as the editing tools have been deployed (modified cells are usually 
harvested and analysed 24-48h after treatment initiation). There is also no need for long-
term follow-up studies as it is the state of the genomic DNA after intervention that is of 
interest, and not the long-term health of the system as a whole. The point is to find out 
whether off-target modifications have occurred or not.  
 
This means that research into this safety issue, even if it is conducted in human embryos, 
can be restricted to a time window of a few hours or days without having to grow the 
embryo further or even bringing it to term. This reduces the risks this research poses to 
close to zero (assuming that destructive research on early-stage embryos does not create 
harm).  
 
At least in the context of off-target effects there is therefore a clear and convincing 
narrative: through more research scientists will be able to optimise the technology so it 
becomes less risky. This will shift the cost/benefit analysis in favour of clinical uses as the 
potential benefits of the applications remain the same whilst the potential costs are 
reduced. Importantly, this is possible because a clear distinction between a safe research 
context and clinical applications can be drawn when it comes to dealing with off-target 
effects. 
 
3.2. Dealing with Unintended Consequences 
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However, off-target effects are only one element of the risk landscape that GGE presents us 
with. The other key element in terms of safety (ignoring legal and social issues) are 
unintended consequences of on-target modifications. Introducing changes in the genome, 
even if the intervention is 100% precise, can have unintended consequences for the 
behaviour of the targeted organism. In the extreme case this could lead to the development 
of disease (e.g. cancer) or negatively affect development and thereby lead to an impairment 
of the modified person. 
 
The key issue here is a lack of knowledge (rather than a methodological limitation). In most 
cases, in particular in the context of complex (i.e. polygenic) diseases, researchers simply 
don’t know enough about the genetics of the conditions in order to proceed in a guided and 
safe manner. 
 
The hope here is, as in the case of off-target effects, that more research will allow 
researchers to eventually remove or significantly reduce this second roadblock to clinical 
applications. This path forward again includes more than just the research use of GGE, as it 
is a broader endeavour that looks at the genetics of disease with a variety of tools, including 
population genetics, the use of in vitro systems, and animal model organisms. 
 
The two problems this research setting has to solve are a) to tell scientists what genes are 
involved in a particular condition or could affect the condition so that targets for genome 
editing can be identified and b) to provide a better understanding of the biological roles 
these potential targets play, as they might be involved in more than one process. 
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Researchers can only interfere with confidence if they know what a genomic element is 
doing (and not just that it affects a particular condition).  
 
What they need, then, is a comprehensive map of DNA elements and their functions. The 
assumption of those calling for a temporary ban on GGE is that the research context 
(understood more broadly than just genome editing research) can provide such a map 
without requiring clinical applications of GGE in humans. The prudent way forward is to 
push ahead with research and to create a map that can guide our genomic interventions 
before actual modified embryos are brought to term. The question is whether the research 
needed to create such a map can be as safe and contained as that used to deal with off-
target effects (section 3.1). 
 
3.3. The Modular Genome 
The idea of the possibility of such a genomic map is partly based on assumptions that have 
dominated genomics for most of the last five decades. In the traditional picture of the 
genome it is seen as a material entity (consisting exclusively of DNA) that contains a set of 
genes. These genes are well-defined entities that can be counted and that have a defined 
structure and function. Their number and composition are a given that does not depend on 
the context, which means that genomes can be studied in spatial isolation and 
independently of developmental time. The map derived from such studies can then be used 
to guide future research and interventions in the genome. 
 
Researchers of course knew for a long time that the environment of the genome cannot be 
completely ignored as some genes, for instance, might only be activated under certain 
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conditions. But in the old view the environment was not a defining element of what that the 
genome and its functional elements look like. There was a clear boundary between the 
genome and what counts as environment.  
 
This picture of the genome and its functioning not only guided large parts of molecular 
biology in the 20th century but also informed, in part at least, the Human Genome Project 
(HGP) and its follow-up projects such as ENCODE (The Encyclopedia of DNA Elements). 
These projects aimed to sequence the human genome (HGP) and to identify and 
characterise all the genes and other functional elements it contains (ENCODE). The guiding 
idea was to map the discrete building blocks of the modular genome.30 
 
These assumptions also have methodological consequences. With this picture of the 
genome in hand there is no need to mix clinical applications with the research context. 
Research into the genome can be done in vitro, in silico, in human cultured cells or in animal 
model systems. Through this work a map of the genome can be created that can tell 
researchers what effects specific interventions might have, thereby allowing them to predict 
which interventions should be safe and which might be potentially dangerous. Human genes 
and their different effects can be studied without having to bring embryos to term. 
 
However, the neat picture of the genome that underlies such a vision has come under 
pressure from findings in the (post-)genomic sciences. In the next section, I will have a 
closer look at these developments. In section 5, I will discuss what this means for the sharp 
distinction between a research and a clinical context. 
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4. The Reactive Genome 
Research in what are now often called the ‘postgenomic’ life sciences (roughly defined as 
the research that followed the completion of the HGP in 2003)31 has fundamentally 
reshaped our understanding of the genome and its functioning.32  
 
There are three extensions to/transformations of the old picture of the genome that I want 
to highlight here. The first transformation relates to the level of nucleotide sequence itself: 
whereas for a long time the genome was thought of as an assembly of genes (connected by 
large stretches of non-functional or ‘junk’ DNA) the HGP and the work done in its wake (in 
particular the ENCODE project) radically changed this understanding.33 As genomicists 
started to realise that there are fewer genes in a human genome than originally thought 
they also found that the majority of non-coding sequences have functional significance and 
could be central to the development and health of the organism.34 This means that the 
number of relevant ‘parts’ of the genome was radically expanded. Moreover, the ENCODE 
project has shown that there isn’t just ‘the’ set of functional elements in a genome. 
Depending on the context, different cells contain different networks of functional 
elements.35 This has led ENCODE researchers to question the idea of ‘completeness’ when it 
comes to creating a map of functional elements.36  
 
All of these new insights also change our understanding of how DNA manipulation could 
affect the health and development of an individual: in the old picture interfering with non-
coding DNA might not have been considered problematic; it was all about interfering with 
genes and their immediate regulatory elements. Now such interventions obtain a new 
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significance as they target sequences that are not just ‘junk’ but that could be functional, 
depending on the context. 
 
The second transformation I want to highlight here included an even more radical extension 
of the elements that are deemed relevant parts of the genome. This transformation is 
closely linked to research in epigenetics (a field that pre-dates the HGP but which made 
significant advances in the post-HGP era). Key to molecular epigenetics is the idea that there 
can be changes to gene expression (and hence the phenotype of an organism) without 
changes to the DNA sequence. Crucial factors that become part of the genome’s functioning 
are methyl groups (covalently attached to cytosine nucleotides) and histone proteins and 
their modifications (for instance acetylation, methylation or sumoylation). 
 
What is important about this second development is that the number of entities that form 
part of a functional genome was extended beyond mere nucleotides; methyl groups and 
histones came to be seen as relevant parts of the genomic system. By that the spatial 
boundary of the genome became extended to such an extent that it has become difficult to 
define the term.37 The notion of “the” genome became much vaguer as a result. 
 
This spatial extension of the genome is also significant because it became part of a third 
transformation of how scientists picture the genome. Up to the 1990s, the genome was 
largely thought of as a timeless entity, a stable set of genes that then shape how the 
organism develops over time. Even though it was known that DNA might accumulate 
mutations over time and that genomes – thought of as part of lineages – are shaped by 
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evolution, at the level of the individual organism the genome was considered to be a well-
defined and largely timeless entity.38 
 
However, as it became clear that the genome is a multi-component entity that is more than 
just a set of genes, it also became clear that the structure and functioning of this system is a 
more complex and dynamic affair. Nowadays the genome is no longer seen as a defined set 
of genes an individual is born with. It is rather seen as a plastic and developing entity the 
composition and functioning of which might significantly change over the lifetime of an 
individual. This also means that the environment now becomes a defining element of what a 
genome looks like and what it does. 
 
To give an example: depending on the events the body is exposed to the genome might 
obtain different methylation patterns in an individual, starting with the embryo in the womb 
(or the culture dish in the case of IVF). These changes will affect how the genome interacts 
with the rest of the body and how it responds to future inputs. What stretches of the 
genome are expressed – and what the expressed products look like – is therefore not simply 
determined by specific genes but by a larger set of entities and processes. As a 
consequence, the behaviour of the genome (as a dynamic multi-component entity) changes 
over the lifetime of an individual and depends on its interactions with other processes in the 
developing body and beyond.39 The functioning of the genome, it turns out, is tightly 
intertwined with its environment (both intra- and extra-cellular) to the point where it 
becomes difficult to think of the two as clearly separated entities. Nutrition, stress level, 




What we are dealing with because of these three transformations is what some authors 
have called a ‘reactive’ genome.41 This is a dynamic system with vague boundaries, both in a 
spatial and also a temporal sense.  
 
This also affects how we think about the organism more generally and its interactions with 
the environment. As Evelyn Fox Keller puts it: 
 
“We have long understood that organisms interact with their environments, that 
interactions between genetics and environment, between biology and culture, 
are crucial to making us what we are. What research in genomics shows is that, 
at every level, biology itself is constituted by those interactions – even at the 
level of genetics”.42 
 
This new understanding of the genome has important methodological consequences for 
biological research: removing a part of the genome or adding a new sequence is not so 
much about removing a well-defined module of the system and replacing it with another, as 
one would manipulate a traditional machine. It is rather like interfering with a complex 
system of interconnected processes, each depending on the presence and activity of the 
other. The effects of such interventions can travel far, both in a temporal and a spatial 
sense.43  
 
5. What Does all of this Mean for the Pursuit of GGE? 
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According to defenders of a temporary ban on clinical uses of GGE there is a clear path to 
ensuring that the benefits of the technology eventually outweigh the risks: by doing more 
research the key safety issues hampering clinical applications can be removed/reduced, thus 
making it possible to propose a time-limited rather than a complete ban. A map of 
functional DNA elements and their physiological importance is central to this plan. 
 
The new picture of the genome that emerges from the postgenomic life sciences creates a 
problem for the neat research/clinical distinction that underlies this strategy. Because of the 
plastic and relational nature of the genome, editing the genome at one stage of 
development can affect later stages of its functioning (and by extension that of the 
organism). This has fundamental consequences for how research into the safety of such 
interventions has to be conducted. 
 
To give an example: removing one part of the genome could affect how other parts are 
methylated. This in turn could have direct consequences for gene expression at later stages 
in the life of the modified organism. To have such wide-ranging effects the removed part of 
the genome would not even have to contain coding sequences, i.e. it is not enough to make 
sure that no essential genes are removed or disrupted by a genome manipulation. The 
edited part could simply contain a sequence that has regulatory significance for methylation 
processes at some stage in the life of the modified organism.  
 
Manipulating a particular DNA sequence can affect the future development and health of an 
organism in new ways as the landscape of stabilised and stabilising processes that make up 
the biological system could be changed by early-stage genomic interventions. Crucially, 
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factors such as nutrition or stress levels, which were traditionally seen as ‘outside’ or ‘non-
biological’ factors, suddenly become intimately linked to the genome itself and its 
modifications. All of these factors have to be taken into account when assessing the possible 
negative effects of a particular genomic intervention. The reactive genome might show 
different reaction norms to future events once we change its DNA. 
 
Dealing with a reactive genome therefore asks for a different approach to research: the 
question of what a particular change in the genome means for its functioning and for the 
health of the individual can only be addressed by considering a) the whole life cycle of the 
modified organism and b) the complex of the individual organism and its environment (if 
such a distinction is still meaningful).44 It is also not enough to just test a modification in 
specific cell types (liver cells, muscle cells, etc.) as a system-wide analysis of the effects of an 
intervention is needed (since all cells of the body are modified when using GGE45 and since 
the behaviour of the reactive genome is highly context-dependent). To achieve a reliable 
estimate of the risks associated with a particular intervention modified human embryos will 
therefore have to be brought to term eventually and their health monitored to an advanced 
age. This means that we have to give up the sharp distinction between a safe research 
context and the clinical use of GGE. It is no longer possible to treat the research context as 
an unproblematic enabler of the clinical context. In the age of the reactive genome research 
and clinical applications become fused, including the risks involved. 
 
5.1. Complex vs. Monogenic Diseases 
As with any absolute statement the above claims have to be qualified. There are certain 
circumstances in which researchers might be able to uphold a distinction between a safe 
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research context and risky clinical applications. I have mentioned one such context above, 
i.e. the investigation of off-target effects (section 3.1). Another is the case of rare 
monogenic diseases. What is special about the latter is that the genetics of these conditions 
are usually relatively simple, as one specific genetic fault is driving the development of the 
condition, often with no or very little influence from other factors such as lifestyle. This 
means that these conditions require only single interventions at a specific locus in the 
genome. In addition, it will often be possible to replace the disease-causing mutation with a 
known variant that is already present in the healthy population. Human population genetics 
can therefore give researchers a good insight into the consequences of carrying the 
replacement sequence. 
 
In the case of complex conditions such as diabetes or heart disease the situation is different. 
First, the genetics of these conditions is not well understood, meaning that researchers 
don’t have a clear picture of potential targets and the roles they might play in the organism. 
Second, as complex conditions are polygenic tackling them via genome editing will require a 
number of edits to see any positive effects of a genomic intervention. Each locus only has a 
small effect on its own and to see a significant impact on disease risk many loci have to be 
changed at once.  
 
This not only means that more targets have to be analysed for potential negative side-
effects but also that the genome is rearranged on a larger scale. The number of edits 
required might range from a dozen to 50 or even hundreds of small and large edits. These 
edits might not only include single-nucleotide replacements or deletions but also the 
deletion of larger junks of genomic DNA or the insertion of sequences that are not found in 
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the healthy population. Such complex interventions could create cumulative effects that go 
beyond those of single edits.46  
 
Because of the reactive nature of the genome any research into possible side-effects of such 
complex interventions will require clinical trials in human subjects. Model organisms or in 
vitro systems using human cells will not be able to give the answers needed as the genomes 
they carry might display very different reaction norms to the ones in an adult modified 
organism.  
 
The reactive genome also means that any such study has to be long-term. Researchers need 
to understand how potential changes affect the reactive genome at any stage of 
development before they can set free genetically-modified organisms. There is little point in 
removing a common variant associated, for instance, with the risk of diabetes if the 
modification turns out to increase the risk of developing early-onset dementia or other 
serious conditions. This means that modified human embryos not only have to be brought 
to term but that the modified trial subjects – who cannot consent to being part of such trials 
– will have to be monitored to an advanced age (without being allowed to further reproduce 
in order to contain the potentially harmful modifications). Assessing the safety of complex 
GGE interventions for common diseases will require an ethically highly questionable trial 
structure.47 These trials mean that, in these cases at least, there is no clear line that can be 




Our scientific picture of the genome is rapidly changing and this also affects how we have to 
think about dealing with the risks of germline editing. In a postgenomic world establishing 
the safety of a genomic modification means to study the whole life cycle of the modified 
organism and its interactions with the environment. This means that the research context 
will also have to include bringing modified embryos to term, at least in the case of complex 
interventions. This in turn means that there is no clear boundary anymore between a safe 
research and a risky clinical context; life, the clinic and research become an interwoven and 
dense assembly.  
 
As a consequence, the costs associated with developing GGE-based solutions for complex 
conditions turns out to be too high to justify them. The research context is no longer a safe 
and innocent enabler of the clinical context, at least not automatically. It might be so in 
some circumstances, for instance when tackling monogenic diseases or when dealing with 
the issue of off-target effects. But in the context of common conditions and the complex 
interventions they require this distinction no longer applies. Once we move towards a 
postgenomic ethics of genome editing the idea of preventing complex diseases through GGE 
becomes morally questionable because of the research required to get to that stage.  
 
In a postgenomic world there seems to be little reason to support a merely temporary ban 
of such clinical applications, as they cannot be obtained without putting humans at 
significant risk of harm. This suggests a mixed strategy for dealing with GGE in humans: 
implement 1) a temporary ban for clinical uses of GGE in the context of monogenic diseases 
and 2) a complete ban for the development of GGE-based treatments of complex diseases. 
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This, of course, does not mean that genome editing should not be used to tackle complex 
conditions. Somatic genome editing remains a powerful weapon and might offer new 
approaches to dealing with common diseases. Several targeted therapies for cancer are 
being developed at the moment.48 What the above analysis shows is simply that the 
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